Joanne T. Beck, Ph.D.
Chief Technology Officer, Aerium Therapeutics
Joanne T. Beck, Ph.D. has served as a member of our Board of Directors since February 2019. Dr. Beck is currently the Chief Technology Officer at Aerium Therapeutics, a position she has held since November 2022. Previously, Dr. Beck was Chief Operating Officer at Boston Pharmaceuticals, a privately held biopharmaceutical company where she currently serves as a Scientific Advisor, from December 2019 to November 2022. From April 2016 to December 2019, Dr. Beck was the Executive Vice President of Global Pharmaceutical Development and Operations at Celgene Corporation, a publicly held biopharmaceutical company. From 2012 to March 2016, Dr. Beck was Senior Vice President of Pharmaceutical Development at Shire Plc, a former publicly held biopharmaceutical company. Prior to Shire, she held positions of increasing responsibility in Global Pharmaceutical Operations at Abbott Laboratories, a publicly held pharmaceuticals and healthcare products company, and was the site head of Abbott Vascular Instruments GmbH. Prior to Abbott, Dr. Beck held positions in Process Development at both Genentech and Amgen. Dr. Beck currently serves as a member of the board of directors of public biopharmaceutical company Orchard Therapeutics. Dr. Beck holds a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco. Dr. Beck also holds a BA in Chemistry from Lewis and Clark College.
